JP2013542194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542194A5 JP2013542194A5 JP2013530383A JP2013530383A JP2013542194A5 JP 2013542194 A5 JP2013542194 A5 JP 2013542194A5 JP 2013530383 A JP2013530383 A JP 2013530383A JP 2013530383 A JP2013530383 A JP 2013530383A JP 2013542194 A5 JP2013542194 A5 JP 2013542194A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- binding fragment
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 102100036008 CD48 antigen Human genes 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000000903 blocking effect Effects 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000046585 human CD48 Human genes 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 101100273713 Homo sapiens CD2 gene Proteins 0.000 claims 1
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000048338 human CD244 Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 208000014242 psoriasis 13 Diseases 0.000 claims 1
- 208000014268 psoriasis 15 Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38674610P | 2010-09-27 | 2010-09-27 | |
| US61/386,746 | 2010-09-27 | ||
| US201161475280P | 2011-04-14 | 2011-04-14 | |
| US61/475,280 | 2011-04-14 | ||
| US201161515490P | 2011-08-05 | 2011-08-05 | |
| US61/515,490 | 2011-08-05 | ||
| PCT/US2011/053193 WO2012047567A1 (en) | 2010-09-27 | 2011-09-26 | Anti-cd48 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016210605A Division JP2017036324A (ja) | 2010-09-27 | 2016-10-27 | 抗ｃｄ４８抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542194A JP2013542194A (ja) | 2013-11-21 |
| JP2013542194A5 true JP2013542194A5 (enExample) | 2014-11-13 |
| JP6096117B2 JP6096117B2 (ja) | 2017-03-15 |
Family
ID=45870888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530383A Expired - Fee Related JP6096117B2 (ja) | 2010-09-27 | 2011-09-26 | 抗ｃｄ４８抗体およびその使用 |
| JP2016210605A Pending JP2017036324A (ja) | 2010-09-27 | 2016-10-27 | 抗ｃｄ４８抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016210605A Pending JP2017036324A (ja) | 2010-09-27 | 2016-10-27 | 抗ｃｄ４８抗体およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9228014B2 (enExample) |
| EP (1) | EP2621952A1 (enExample) |
| JP (2) | JP6096117B2 (enExample) |
| KR (1) | KR20140014067A (enExample) |
| CN (1) | CN103261226B (enExample) |
| AR (1) | AR083044A1 (enExample) |
| AU (1) | AU2011312623B2 (enExample) |
| BR (1) | BR112013007314A2 (enExample) |
| CA (1) | CA2812748A1 (enExample) |
| CL (1) | CL2013000843A1 (enExample) |
| EA (1) | EA030437B1 (enExample) |
| IL (1) | IL225484A (enExample) |
| MX (1) | MX348417B (enExample) |
| MY (1) | MY165273A (enExample) |
| NZ (1) | NZ608660A (enExample) |
| PH (1) | PH12013500564A1 (enExample) |
| SG (1) | SG189089A1 (enExample) |
| TW (1) | TWI507416B (enExample) |
| WO (1) | WO2012047567A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9533039B2 (en) * | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| RS64172B1 (sr) | 2012-06-28 | 2023-05-31 | Univ Of Central Florida Research Foundation Incorporated | Postupci i kompozicije za ćelije prirodne ubice |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| EP3189077A2 (en) * | 2014-09-05 | 2017-07-12 | Aimm Therapeutics B.V. | Hepatitis c virus specific antibody |
| MX382582B (es) * | 2015-03-18 | 2025-03-13 | Seagen Inc | Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados. |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| JP6805884B2 (ja) | 2017-02-28 | 2020-12-23 | 住友ゴム工業株式会社 | 二輪自動用空気入りタイヤ |
| EP3649144A4 (en) | 2017-07-06 | 2021-07-21 | Regeneron Pharmaceuticals, Inc. | CELL CULTURE PROCESS TO PRODUCE GLYCOPROTEIN |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| SG11202005235WA (en) | 2018-01-31 | 2020-07-29 | Regeneron Pharma | System and method for characterizing size and charge variant drug product impurities |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| BR112020024296A2 (pt) | 2018-08-27 | 2021-03-09 | Regeneron Pharmaceuticals, Inc. | Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína |
| KR20210053816A (ko) | 2018-08-30 | 2021-05-12 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 복합체를 특성화하기 위한 방법 |
| EA202191841A1 (ru) | 2019-01-16 | 2021-10-07 | Ридженерон Фармасьютикалз, Инк. | Способы для идентификации свободных тиолов в белках |
| EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| IL317159A (en) | 2019-09-24 | 2025-01-01 | Regeneron Pharma | Systems and methods for use in chromatography and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| AU2020394428B2 (en) | 2019-11-25 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| MY200781A (en) | 2020-01-21 | 2024-01-15 | Regeneron Pharma | Deglycosylation methods for electrophoresis of glycosylated proteins |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| WO2022047108A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| MX2023006010A (es) * | 2020-11-24 | 2023-06-08 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos. |
| MX2023006077A (es) | 2020-11-25 | 2023-06-06 | Regeneron Pharma | Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. |
| CA3205135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
| AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
| AU2022243005A1 (en) | 2021-03-26 | 2023-10-05 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| MX2023014246A (es) | 2021-06-01 | 2024-01-17 | Regeneron Pharma | Ensayos y reactivos de microchips de electroforesis capilar. |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| IL311527A (en) | 2021-09-20 | 2024-05-01 | Regeneron Pharma | Methods for controlling antibody heterogeneity |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| CN118176167A (zh) | 2021-10-26 | 2024-06-11 | 瑞泽恩制药公司 | 用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法 |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| TW202435942A (zh) | 2022-12-16 | 2024-09-16 | 美商里珍納龍藥品有限公司 | 評估層析管柱完整性的方法及系統 |
| EP4655595A1 (en) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024158880A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| US20240255519A1 (en) | 2023-02-01 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| KR20240147948A (ko) * | 2023-03-29 | 2024-10-10 | 웰마커바이오 주식회사 | Igsf1 특이적 결합 단백질 및 이의 용도 |
| WO2024229136A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| WO2025096932A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692405A (en) | 1985-03-05 | 1987-09-08 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies to antigen on activated human B-cells and assay therefor, protein antigenic determinant therefor and method of making same |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| WO1997035614A1 (en) * | 1996-03-27 | 1997-10-02 | Crc For Biopharmaceutical Research Pty. Ltd. | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| WO2005094886A1 (ja) | 2004-03-31 | 2005-10-13 | Kirin Beer Kabushiki Kaisha | Gpiアンカー蛋白質アゴニストによる調節性t細胞分化誘導・増殖方法およびそのための医薬組成物 |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8409565B2 (en) | 2006-02-14 | 2013-04-02 | Francesca Levi-Schaffer | Therapeutic target and diagnostic marker for asthma and related conditions |
| WO2007143168A2 (en) | 2006-06-02 | 2007-12-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| JP5566374B2 (ja) | 2009-04-10 | 2014-08-06 | 国立大学法人大阪大学 | 形質細胞の腫瘍性増殖をきたす疾患の治療薬 |
-
2011
- 2011-09-19 AR ARP110103412A patent/AR083044A1/es unknown
- 2011-09-26 MX MX2013003468A patent/MX348417B/es active IP Right Grant
- 2011-09-26 EA EA201370081A patent/EA030437B1/ru not_active IP Right Cessation
- 2011-09-26 MY MYPI2013700476A patent/MY165273A/en unknown
- 2011-09-26 AU AU2011312623A patent/AU2011312623B2/en not_active Ceased
- 2011-09-26 EP EP11764071.4A patent/EP2621952A1/en not_active Withdrawn
- 2011-09-26 WO PCT/US2011/053193 patent/WO2012047567A1/en not_active Ceased
- 2011-09-26 CA CA2812748A patent/CA2812748A1/en active Pending
- 2011-09-26 KR KR1020137008885A patent/KR20140014067A/ko not_active Abandoned
- 2011-09-26 NZ NZ60866011A patent/NZ608660A/en not_active IP Right Cessation
- 2011-09-26 PH PH1/2013/500564A patent/PH12013500564A1/en unknown
- 2011-09-26 TW TW100134591A patent/TWI507416B/zh not_active IP Right Cessation
- 2011-09-26 BR BR112013007314A patent/BR112013007314A2/pt active Search and Examination
- 2011-09-26 CN CN201180054278.1A patent/CN103261226B/zh not_active Expired - Fee Related
- 2011-09-26 SG SG2013022173A patent/SG189089A1/en unknown
- 2011-09-26 JP JP2013530383A patent/JP6096117B2/ja not_active Expired - Fee Related
- 2011-09-26 US US13/244,960 patent/US9228014B2/en active Active
-
2013
- 2013-03-24 IL IL225484A patent/IL225484A/en active IP Right Grant
- 2013-03-27 CL CL2013000843A patent/CL2013000843A1/es unknown
-
2016
- 2016-10-27 JP JP2016210605A patent/JP2017036324A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542194A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| JP2015535828A5 (enExample) | ||
| JP2012523417A5 (enExample) | ||
| JP2014512809A5 (enExample) | ||
| ME02798B (me) | Protutijela protiv dkk-1" | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2013542191A5 (enExample) | ||
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| JP2014526898A5 (enExample) | ||
| RU2013145243A (ru) | Гуманизированные антитела к ctla4 | |
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| RU2018110064A (ru) | Антитела к бета-амилоиду | |
| RU2015110981A (ru) | Комбинации и их применение | |
| NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
| RU2019104980A (ru) | Анти-icos антитела | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |